Vir Reports First Patient Dosing in P-II MARCH Trial for VIR-2218 + VIR-3434 as a Functional Cure Regimen for Chronic Hepatitis B Virus Infection

 Vir Reports First Patient Dosing in P-II MARCH Trial for VIR-2218 + VIR-3434 as a Functional Cure Regimen for Chronic Hepatitis B Virus Infection

Vir Reports First Patient Dosing in P-II MARCH Trial for VIR-2218 + VIR-3434 as a Functional Cure Regimen for Chronic Hepatitis B Virus Infection

Shots:

  • The 1st patient has been dosed in the P-II MARCH trial evaluating safety, tolerability & efficacy of VIR-2218 + VIR-3434 (SC) in ~90 patients aged 18-65yrs. with chronic HBV infection for 4-20wks. & follow-up period of ~116 wks., depend on dosing cohort
  • The 1EPs of a trial is the proportion of patients with AEs & SAEs, grading of post-treatment clinical laboratory parameters & proportion of patients achieving a functional cure
  • VIR-2218 is an investigational HBV-targeting siRNA & VIR-3434 is an HBV-neutralizing mAb designed to block entry of all 10 genotypes of HBV into hepatocytes, as well as reduce the level of virions and subviral particles in the blood

Click here to­ read the full press release/ article | Ref: Vir | Image: Fierce Biotech

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post